Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 94 of 102, showing 5 Applications out of 508 total, starting on record 466, ending on 470

# Protocol No Study Title Investigator(s) & Site(s)

466.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
View

467.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Prof Walter Jaoko Godfrey Jaoko
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
View

468.

ECCT/17/09/01   HPTN 084
    HPTN 084:   A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women         
Principal Investigator(s)
1. Samuel Gurrion Ouma
Site(s) in Kenya
KISUMU CRS
 
View

469.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View

470.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
View